Core Viewpoint - The company emphasizes that sustainable and stable shareholder returns are built on high-quality and sustainable development, focusing on core business, optimizing management, and enhancing profitability [1] Group 1: Company Overview - Dalian Bai'ao Chemical Co., Ltd. specializes in the research, production, and sales of isothiazolinone industrial biocide raw materials and has been in the industry for over 20 years, becoming the largest producer of such biocides in Asia [1] - In 2024, the company transitioned into the semiconductor equipment sector through its controlling stake in Suzhou Xinhuilian Semiconductor Technology Co., Ltd. and a stake in Xinhuilian New (Suzhou) Technology Co., Ltd., establishing a dual business model of industrial biocides and semiconductor equipment [1] Group 2: Financial Performance - In the first half of the year, the company reported revenue of 749 million yuan, a year-on-year increase of 28.42%, while net profit attributable to shareholders decreased by 44.22% to 91.79 million yuan [2] - The chemical business faced challenges due to external environmental factors, weak market demand, and continuously low prices, leading to sustained pressure on profitability [2] Group 3: Business Segments - The company’s industrial biocide products are primarily exported to Asia, Europe, the United States, and South America, with overall changes remaining stable [2] - Despite the pressure on profitability in the biocide segment, there are positive signs, such as a 7.69% increase in average sales prices of biocide products in the second quarter and a 21.37% decrease in the comprehensive procurement costs of key raw materials [2] - The semiconductor equipment business, led by the subsidiary Xinhuilian, remains a core strategic direction, focusing on technology development, market expansion, and operational stability [3]

Core Viewpoint - Dalian Bio-Chem Company Limited reported a significant increase in revenue but a substantial decline in net profit for the first half of 2025, indicating challenges in profitability despite growth in sales [2][3]. Financial Performance - The company achieved operating revenue of approximately 748.56 million yuan, a year-on-year increase of 28.42% compared to 582.92 million yuan in the same period last year [2]. - Total profit decreased by 38.53% to 114.83 million yuan from 186.80 million yuan [2]. - Net profit attributable to shareholders fell by 44.22% to 91.79 million yuan from 164.55 million yuan [2]. - The net cash flow from operating activities was negative at -5.68 million yuan, a decline of 109.87% from 57.50 million yuan [2]. Industry Overview - The company operates in the isothiazolinone industrial biocide sector, which has become a mainstream non-oxidizing biocide with a high concentration of production capacity among a few leading enterprises [3]. - The semiconductor industry, a core area for the company, continues to grow rapidly, driven by advancements in 5G, artificial intelligence, and data centers [3]. Business Segments - The company specializes in the research, production, and sales of isothiazolinone industrial biocides, with a production capacity exceeding 40,000 tons per year, making it the largest producer in Asia [3][4]. - The semiconductor segment, through its subsidiary, focuses on providing wafer sorting and front-end module equipment, contributing to the domestic semiconductor industry's localization efforts [5][6]. Strategic Focus - The company aims to enhance its core competitiveness and risk resistance through a dual business strategy in chemicals and semiconductors, emphasizing research and development and talent cultivation [7]. - Safety production measures are strictly implemented to ensure stable operations and high-quality development [8]. Investment Activities - The company made significant investments in its semiconductor business, including a capital increase in its subsidiary to strengthen its market position [9][14].

Core Viewpoint - Dalian Bai'ao Chemical Co., Ltd. is successfully transforming its business towards semiconductor equipment, showcasing significant growth in its high-end lithography machine segment and a strong order backlog [1][2]. Company Overview - Bai'ao Chemical has over 20 years of experience in the industrial biocide industry, with an annual production capacity exceeding 40,000 tons, making it the largest producer of isothiazolinone-based industrial biocide raw materials in Asia [1]. - The company has established semiconductor equipment as a strategic development direction in early 2024, marking a significant shift from its traditional industrial biocide business [1]. Semiconductor Equipment Business - Bai'ao Chemical acquired 54.63% voting rights in Suzhou Xinhuilian Semiconductor Technology Co., Ltd. (Xinhuilian) through capital increase and voting rights entrustment, integrating it into the company's consolidated financial statements [1]. - Xinhuilian specializes in the R&D, production, and sales of semiconductor equipment, with six major business segments including photolithography equipment and wet cleaning equipment [2]. Financial Performance - In 2024, Xinhuilian achieved operating revenue of 543 million yuan, a year-on-year increase of 215.75%, and a net profit attributable to shareholders of 97 million yuan, up 370.82% year-on-year [2]. - The gross profit margin for Xinhuilian was 51.31%, an increase of 20.12 percentage points compared to the previous year, with the photolithography equipment segment boasting a gross margin of 71.56% [2]. Customer Contracts - As of the end of 2024, Xinhuilian's top five customers had a total contract amount of 1.369 billion yuan, with over 1 billion yuan in contracts yet to be recognized as revenue [2][3]. - One significant customer accounted for a contract amount of 492 million yuan, including two major contracts for photolithography equipment scheduled for delivery in 2025 [3]. Market Outlook - The semiconductor equipment market is expected to experience rapid growth due to the increasing demand for specialized equipment and the domestic semiconductor industry's advancements [1][3].

Core Viewpoint - The company, Dalian Baiao Chemical Co., Ltd., reported a revenue of 1.312 billion yuan for its industrial biocide business in 2024, reflecting a year-on-year growth of 23.09%. However, the gross profit margin decreased by 8.28 percentage points to 44.30% due to increased competition and pricing pressures in the market [2][5]. Group 1: Financial Performance - The industrial biocide business generated 1.207 billion yuan in revenue, accounting for 92% of the main business income, with over 60% of this revenue coming from overseas markets [2][3]. - The company’s overseas revenue from 2021 to 2024 showed an upward trend, increasing from 471 million yuan in 2021 to 762 million yuan in 2024 [2]. - The average selling price of industrial biocide products decreased by 14.95%, while the unit cost increased by 0.70%, leading to an overall decline in gross profit margin [5][6]. Group 2: Product and Market Analysis - The company specializes in the research, production, and sales of isothiazolinone-based industrial biocides, with no direct competitors listed in the public market [5][6]. - The average sales prices of key products, such as CMIT/DCOIT and BIT series, experienced significant declines, with CMIT/DCOIT prices dropping by 25.03% [5][6]. - The company faced increased competition as domestic manufacturers expanded production capacity, leading to downward pressure on product prices [5][6]. Group 3: Customer and Supply Chain Insights - The company provided details on its top ten overseas customers, including their sales amounts and operational details, confirming that there are no related party transactions with these customers [8][9]. - The logistics and transportation costs for overseas sales have fluctuated significantly, with transportation expenses rising by 129.37% in 2024 compared to the previous year [10][11]. - The company’s overseas business transportation costs were primarily borne by the company, with major carriers being large international shipping companies [10][11]. Group 4: Semiconductor Business Overview - In 2024, the company acquired a 54.63% stake in Chipwise, which achieved a net profit of 103.29% of its performance commitment, indicating strong operational performance [13][14]. - Chipwise's revenue for 2024 reached 543.46 million yuan, with a significant increase in gross profit margin due to successful product lines [16][18]. - The company’s cash flow from operating activities for Chipwise remained negative, primarily due to high procurement costs for semiconductor equipment [17][18].